Drug discovery and chemokine receptor antagonists: eppur si muove!
The blockade of leukocyte migration has been demonstrated to be a valid option for the treatment of several autoimmune diseases. Chemokines play an active role in regulating cell infiltration into inflammatory sites and disrupting chemokine-receptor interactions has emerged as an alternative therapeutic approach. Pharmaceutical companies have developed an intense activity in the drug discovery of chemokine receptor antagonists in the last 10 years. Potent and selective compounds have been obtained and some of them are currently being evaluated in the clinic. The success of these trials will demonstrate whether the blockade of a single receptor is of therapeutic benefit. Alternative approaches, such as pan-receptor antagonists or inhibitors of the signalling pathways evoked by chemokines, are also being explored. In the meantime, new relationships between chemokines and receptors will be revealed, increasing our knowledge of such a fascinating field.
Terricabras
Emma
E
Department of Biology, Almirall Research Center, Cardener 68-74, 08024 Barcelona, Spain.
Benjamim
Claudia
C
Godessart
Nuria
N
D000818:Animals; D002465:Cell Movement / Q000502:physiology*; D015195:Drug Design; D006801:Humans; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*
D019707:Receptors, Chemokine